Cancer immunotherapy using dendritic/tumour-fusion vaccine induces elevation of serum anti-nuclear antibody with better clinical responses.
Dendritic cell (DC) vaccines might induce both anti-tumour immunity and autoimmunity. In this report, we demonstrate elevated levels of anti-nuclear antibody (ANA) in the sera of patients with cancer who had received immunotherapy with a dendritic/tumour-fusion vaccine. Twenty-two patients were treated with DC vaccine of fusion cells composed of autologous DCs and tumour cells (DC/tumour-fusion vaccine), which was generated by treating each cell type with polyethylene glycol. Nine of the 22 patients were treated with both the DC/tumour-fusion vaccine and systemic administration of recombinant human interleukin (rhIL)-12. Serum levels of ANA were examined with an enzyme-linked immunosorbent assay kit. One patient with gastric carcinoma (patient 1, DC/tumour-fusion vaccine alone), one patient with breast cancer (patient 2, DC/tumour-fusion vaccine alone) and one patient with ovarian cancer (patient 3, DC/tumour-fusion vaccine + rhIL-12) showed significant elevations of serum ANA levels during treatment. In patient 1 malignant ascitic effusion resolved and serum levels of tumour markers decreased. Patients 2 and 3 remained in good physical condition during treatment for 24 and 9 months, respectively. Immunoblot analysis indicated antibody responses to autologous tumour cells after vaccination in patient 2. None of the treated patients showed clinical symptoms suggesting autoimmune disease. Patients with elevated serum levels of ANA had significantly longer treatment periods than those without it. Elevated serum levels of ANA after DC/tumour-fusion cell vaccine might be associated with anti-tumour immune response induced by the vaccination.
Department of Oncology, Institute of DNA Medicine, Jikei University School of Medicine, Nishi-shimbashi, Tokyo, Japan. sahya@jikei.ac.jp
S
S
Homma
Y
Y
Sagawa
M
M
Ito
T
T
Ohno
G
G
Toda
D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000097:blood*; D000912:Antibodies, Neoplasm / Q000097:blood; D001323:Autoantibodies / Q000097:blood; D001327:Autoimmune Diseases / Q000276:immunology; D001943:Breast Neoplasms / Q000097:blood / Q000276:immunology / Q000628:therapy; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D018664:Interleukin-12 / Q000627:therapeutic use; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000276:immunology / Q000628:therapy*; D010051:Ovarian Neoplasms / Q000097:blood / Q000276:immunology / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome; D014407:Tumor Cells, Cultured
D000974:Antibodies, Antinuclear; D000912:Antibodies, Neoplasm; D001323:Autoantibodies; D019496:Cancer Vaccines; D011994:Recombinant Proteins; D018664:Interleukin-12